OS Therapies Incorporated Net Income
| OSTX Stock | 1.17 0.04 3.31% |
As of the 19th of February, OS Therapies owns the market risk adjusted performance of (0.37), and Information Ratio of (0.18). In connection with fundamental indicators, the technical analysis model allows you to check timely technical drivers of OS Therapies, as well as the relationship between them.
OS Therapies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing OS Therapies' valuation are provided below:We have found one hundred thirteen available fundamental measures for OS Therapies, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to check out all of OS Therapies latest market performance against the performance between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond. Market Cap is likely to drop to about 51.1 M in 2026. Enterprise Value is likely to drop to about 56.4 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -10.2 M | -10.7 M | |
| Net Loss | -8 M | -8.4 M | |
| Net Loss | (0.49) | (0.51) |
OSTX | Net Income | Build AI portfolio with OSTX Stock |
The evolution of Net Income for OS Therapies Incorporated provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how OS Therapies compares to historical norms and industry peers.
Latest OS Therapies' Net Income Growth Pattern
Below is the plot of the Net Income of OS Therapies Incorporated over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in OS Therapies financial statement analysis. It represents the amount of money remaining after all of OS Therapies Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is OS Therapies' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OS Therapies' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.88 M) | 10 Years Trend |
|
Net Income |
| Timeline |
OSTX Net Income Regression Statistics
| Arithmetic Mean | (2,753,222) | |
| Coefficient Of Variation | (140.47) | |
| Mean Deviation | 3,555,193 | |
| Median | (6,027) | |
| Standard Deviation | 3,867,435 | |
| Sample Variance | 15T | |
| Range | 8.9M | |
| R-Value | (0.84) | |
| Mean Square Error | 4.7T | |
| R-Squared | 0.71 | |
| Significance | 0.000025 | |
| Slope | (643,269) | |
| Total Sum of Squares | 239.3T |
OSTX Net Income History
Other Fundumenentals of OS Therapies
OSTX Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for OS Therapies is extremely important. It helps to project a fair market value of OSTX Stock properly, considering its historical fundamentals such as Net Income. Since OS Therapies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OS Therapies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OS Therapies' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OS Therapies. Anticipated expansion of OSTX directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive OS Therapies assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of OS Therapies is measured differently than its book value, which is the value of OSTX that is recorded on the company's balance sheet. Investors also form their own opinion of OS Therapies' value that differs from its market value or its book value, called intrinsic value, which is OS Therapies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OS Therapies' market value can be influenced by many factors that don't directly affect OS Therapies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between OS Therapies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OS Therapies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, OS Therapies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
OS Therapies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to OS Therapies' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of OS Therapies.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in OS Therapies on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding OS Therapies Incorporated or generate 0.0% return on investment in OS Therapies over 90 days. OS Therapies is entity of United States. It is traded as Stock on NYSE MKT exchange. More
OS Therapies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure OS Therapies' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess OS Therapies Incorporated upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 16.39 | |||
| Value At Risk | (5.81) | |||
| Potential Upside | 5.56 |
OS Therapies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for OS Therapies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as OS Therapies' standard deviation. In reality, there are many statistical measures that can use OS Therapies historical prices to predict the future OS Therapies' volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.38) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of OS Therapies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
OS Therapies February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.37) | |||
| Mean Deviation | 3.2 | |||
| Coefficient Of Variation | (584.97) | |||
| Standard Deviation | 3.93 | |||
| Variance | 15.42 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.38) | |||
| Maximum Drawdown | 16.39 | |||
| Value At Risk | (5.81) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.0783 | |||
| Kurtosis | (0.34) |
OS Therapies Backtested Returns
OS Therapies retains Efficiency (Sharpe Ratio) of -0.14, which implies the firm had a -0.14 % return per unit of price deviation over the last 3 months. OS Therapies exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check OS Therapies' market risk adjusted performance of (0.37), and Information Ratio of (0.18) to confirm the risk estimate we provide. The company owns a Beta (Systematic Risk) of 1.79, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, OS Therapies will likely underperform. At this point, OS Therapies has a negative expected return of -0.56%. Please make sure to check OS Therapies' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if OS Therapies performance from the past will be repeated sooner or later.
Auto-correlation | 0.82 |
Very good predictability
OS Therapies Incorporated has very good predictability. Overlapping area represents the amount of predictability between OS Therapies time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of OS Therapies price movement. The serial correlation of 0.82 indicates that around 82.0% of current OS Therapies price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.82 | |
| Spearman Rank Test | 0.71 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, OS Therapies Incorporated reported net income of (8.88 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
OSTX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OS Therapies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OS Therapies could also be used in its relative valuation, which is a method of valuing OS Therapies by comparing valuation metrics of similar companies.OS Therapies is currently under evaluation in net income category among its peers.
OSTX Fundamentals
| Return On Equity | -9.14 | ||||
| Return On Asset | -2.25 | ||||
| Current Valuation | 59.56 M | ||||
| Shares Outstanding | 35.21 M | ||||
| Shares Owned By Insiders | 27.99 % | ||||
| Shares Owned By Institutions | 5.31 % | ||||
| Number Of Shares Shorted | 965.73 K | ||||
| Price To Book | 11.81 X | ||||
| EBITDA | (6.83 M) | ||||
| Net Income | (8.88 M) | ||||
| Total Debt | 6.05 M | ||||
| Book Value Per Share | 0.11 X | ||||
| Cash Flow From Operations | (7.28 M) | ||||
| Short Ratio | 1.41 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 11.49 | ||||
| Market Capitalization | 42.61 M | ||||
| Total Asset | 5.54 M | ||||
| Retained Earnings | (40.4 M) | ||||
| Working Capital | 906.22 K | ||||
| Net Asset | 5.54 M |
About OS Therapies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OS Therapies Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OS Therapies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OS Therapies Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OSTX Stock Analysis
When running OS Therapies' price analysis, check to measure OS Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OS Therapies is operating at the current time. Most of OS Therapies' value examination focuses on studying past and present price action to predict the probability of OS Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OS Therapies' price. Additionally, you may evaluate how the addition of OS Therapies to your portfolios can decrease your overall portfolio volatility.